

Integrated multiple analytes and semi-mechanistic population pharmacokinetic model of tusamitamab ravtansine, a DM4 anti-CEACAM5 antibody-drug conjugate


*Journal of Pharmacokinetics and Pharmacodynamics*

Clemence Pouzin, Leonid Gibiansky, Nathalie Fagniez, Michel Tod, Mustapha Chadjaa, Laurent Nguyen


Corresponding author: Clemence Pouzin, 1 Avenue Pierre Brossolette, 91380 Chilly-Mazarin, France. Email: [Clemence.Pouzin@sanofi.fr](mailto:Clemence.Pouzin@sanofi.fr)

Online Resource 3: GOF plots, observed data vs population and individual prediction


a. SAR408701




b. DM4





### c. MeDM4





### d. NAB




e. Average DAR




f. Proportions of individual DAR species: NAB (DAR0)





### g. Proportions of individual DAR species: DAR1





### h. Proportions of individual DAR species: DAR2





i. Proportions of individual DAR species: DAR3





j. Proportions of individual DAR species: DAR4



k. Proportions of individual DAR species: DAR5



l. Proportions of individual DAR species: DAR6



m. Proportions of individual DAR species: DAR7

